Lilly drug slows Alzheimers by 35 bolstering treatment approach Reuters

CHICAGO, May 3 (Reuters) – An experimental Alzheimer’s drug developed by Eli Lilly and Co (LLY.N) slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what … [+4726 chars]Read More